Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29392833 | 0.98 | SNCA (0.60) | SNCAHIF1APLA2G1BATG4BIDO1 | |
| SCHEMBL29751859 | 0.98 | SNCA (0.60) | SNCAHIF1APLA2G1BATG4BIDO1 | |
| Hydrochloric Acid SCHEMBL376693 | 0.96 | SNCA (0.58) | SNCAHIF1APLA2G1BATG4BIDO1 | |
| Iodide SCHEMBL5462695 | 0.96 | SNCA (0.58) | SNCAHIF1APLA2G1BATG4BIDO1 | |
| SCHEMBL8605747 | 0.90 | SNCA (0.53) | SNCAHIF1APLA2G1BATG4BIDO1 | |
| SCHEMBL8375928 | 0.90 | SNCA (0.53) | SNCAHIF1APLA2G1BATG4BIDO1 | |
| SCHEMBL8376764 | 0.90 | SNCA (0.53) | SNCAHIF1APLA2G1BATG4BIDO1 | |
| Bromide SCHEMBL39844 | 0.89 | SNCA (0.73) | SNCAHIF1AALDH1A1CYP3A4EPHX1 | |
| Iodide SCHEMBL9321342 | 0.84 | SNCA (0.69) | SNCAHIF1AALDH1A1CYP3A4EPHX1 | |
| Hydrochloric Acid SCHEMBL2446696 | 0.84 | SNCA (0.69) | SNCAHIF1AALDH1A1CYP3A4EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114249718-A | Sulfonium salt derivative and preparation method and medical application thereof | 中国药科大学 | 2022-03-29 | — | — | CN | claimed |
| US-20250282742-A1 | BENZOFURAN DERIVATIVES FOR TARGETING AUTOPHAGY | Automera PTE. LTD (SG) | 2025-09-11 | — | — | US | disclosed |
| EP-3687538-B1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INST (CA) | 2024-04-17 | — | — | EP | disclosed |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2024-03-19 | — | — | US | disclosed |
| CN-114249718-B | Sulfonium salt derivative, preparation method and medical application thereof | 中国药科大学 | 2023-09-22 | — | — | CN | disclosed |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | Montréal Heart Institute (CA) | 2023-03-23 | — | — | US | disclosed |
| US-11530186-B2 | Inhibitors for the β-catenin / T-cell factor protein-protein interaction | H. Lee Moffitt Cancer Center and Research Center Institute, Inc. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2022-08-02 | — | — | US | disclosed |
| CN-114249718-A | Sulfonium salt derivative and preparation method and medical application thereof | 中国药科大学 | 2022-03-29 | — | — | CN | disclosed |
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INSTITUTE (CA) | 2021-12-02 | — | — | US | disclosed |
| EP-0315050-B1 | ALCENYL BICYCLOHEXANES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-09-01 | — | — | EP | disclosed |
| US-5230826-A | HALOBENZENE LIQUID CRYSTALS | HOFFMANN-LA ROCHE INC. (US) | 1993-07-27 | — | — | US | disclosed |
| CN-1016336-B | Olefines pesticide composition and preparation method thereof | ICI PLC (GB) | 1992-04-22 | — | — | CN | disclosed |
| US-5013477-A | Alkenylbicyclohexane liquid crystals | HOFFMANN-LA ROCHE INC. (US) | 1991-05-07 | — | — | US | disclosed |
| EP-0220810-B1 | INSECTICIDAL ETHERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-02 | — | — | EP | disclosed |
| EP-0315014-A2 | Halogenated benzene derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-05-10 | — | — | EP | disclosed |
| EP-0315050-A2 | Alcenyl bicyclohexanes | F. HOFFMANN-LA ROCHE AG (CH) | 1989-05-10 | — | — | EP | disclosed |
| US-4788348-A | HYDROXY AROMATIC ETHERS AS CHEMICAL INTERMEDIATES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-11-29 | — | — | US | disclosed |
| US-4705900-A | Insecticidal alkenes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-11-10 | — | — | US | disclosed |
| EP-0220810-A1 | Insecticidal ethers | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530186-B2 | Inhibitors for the β-catenin / T-cell factor protein-protein interaction | CTNNB1, CTNNBL1, APC | SNCA 4648/4885HIF1A 3400/4885PLA2G1B 2345/4885 |
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | SNCA 4651/4885HIF1A 2791/4885PLA2G1B 1217/4885 |
| US-20250282742-A1 | BENZOFURAN DERIVATIVES FOR TARGETING AUTOPHAGY | SQSTM1, BECN1, TFEB | SNCA 67/4885HIF1A 704/4885PLA2G1B 4303/4885 |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | SNCA 4651/4885HIF1A 2791/4885PLA2G1B 1217/4885 |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | SNCA 4651/4885HIF1A 2791/4885PLA2G1B 1217/4885 |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | SNCA 4651/4885HIF1A 2791/4885PLA2G1B 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.